{"id":46149,"date":"2025-11-08T14:54:58","date_gmt":"2025-11-08T06:54:58","guid":{"rendered":"https:\/\/flcube.com\/?p=46149"},"modified":"2025-11-08T14:54:59","modified_gmt":"2025-11-08T06:54:59","slug":"zai-lab-q3-2025-revenue-up-13-yoy-to-115-4-m-led-by-nuzyra-and-xacduo-zejula-slows","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46149","title":{"rendered":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows"},"content":{"rendered":"\n<p><strong>Zai Lab Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ: ZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG: 9688<\/a>) released its third\u2011quarter 2025 financial results, reporting total net product revenue of <strong>USD\u202f115.4\u202fmillion<\/strong>, a <strong>13\u202f% year\u2011over\u2011year increase<\/strong> (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of <strong>Nuzyra (omadacycline)<\/strong> and <strong>Xacduro (Sulbactam\u2011Durlobactam)<\/strong>, partially offset by a slowdown in <strong>Zejula (niraparib)<\/strong> sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-financial-highlights\">Key Financial Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025\u202fQ3<\/th><th>2024\u202fQ3<\/th><th>% YoY<\/th><\/tr><\/thead><tbody><tr><td>Net Product Revenue<\/td><td>$115.4\u202fM<\/td><td>$101.8\u202fM<\/td><td><strong>+13\u202f%<\/strong> (14\u202f% at CER)<\/td><\/tr><tr><td>FY\u202f2025 2025 Revenue Guidance<\/td><td>\u2265$460\u202fM<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Revenue distribution by product<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nuzyra (omadacycline)<\/strong>: $15.4\u202fM (\u2191\u202f54\u202f% YoY)<\/li>\n\n\n\n<li><strong>Xacduro (Sulbactam\u2011Durlobactam)<\/strong>: $6.4\u202fM (first\u2011quarter launch)<\/li>\n\n\n\n<li><strong>Zejula (niraparib)<\/strong>: $42.4\u202fM (\u2193\u202f12\u202f% YoY)<\/li>\n\n\n\n<li><strong>Vyvgart \/ Vyvgart Hytrulo<\/strong>: $27.7\u202fM (\u2191\u202f4.6\u202f% QoQ)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-specific-performance\">Product\u2011Specific Performance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-nuzyra-omadacycline\">Nuzyra (Omadacycline)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Growth driver<\/strong>: Expanded market coverage and deeper penetration into the outpatient respiratory infection segment.<\/li>\n\n\n\n<li><strong>YoY comparison<\/strong>: $15.4\u202fM vs $10.0\u202fM (2024\u202fQ3).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-xacduro-sulbactam-durlobactam\">Xacduro (Sulbactam\u2011Durlobactam)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Launch\u2011phase success<\/strong>: Launched in Q4\u202f2024; $6.4\u202fM revenue in Q3\u202f2025 reflects strong uptake among hospitals treating carbapenem\u2011resistant gram\u2011negative infections.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-zejula-niraparib\">Zejula (Niraparib)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive pressure<\/strong>: 12\u202f% YoY decline to $42.4\u202fM, attributed to influx of new PARP\u2011inhibitor entrants and pricing negotiations.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vyvgart-vyvgart-hytrulo\">Vyvgart \/ Vyvgart Hytrulo<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing strategy<\/strong>: $2.4\u202fM revenue dip in Q3\u00a02025 due to proactive price realignment ahead of China\u2019s National Reimbursement Drug List (NRDL) talks; overall Q3 sales still up 4.6\u202f% QoQ thanks to improved market penetration and longer treatment durations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-guidance-amp-outlook\">Guidance &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full\u2011Year Revenue<\/strong>: Adjusted to <strong>\u2265USD\u202f460\u202fmillion<\/strong> for FY\u202f2025, reflecting the momentum of the above product mix.<\/li>\n\n\n\n<li><strong>Strategic Focus<\/strong>: Zai Lab aims to accelerate market penetration for Nuzyra across Tier\u20112\/3 cities and expand Xacduro\u2019s distribution in the U.S. pipeline.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: The firm monitors emerging PARP\u2011inhibitors and continues to negotiate NRDL pricing to safeguard revenue streams.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements about regulatory approvals, market adoption, pricing strategy, and commercial expectations. Actual results may differ due to factors including competitive dynamics, regulatory changes, and macroeconomic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/11908894-0.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 11908894-0.\"><\/object><a id=\"wp-block-file--media-a52e0258-9934-4b55-9ebf-2b855eca0fd3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/11908894-0.pdf\">11908894-0<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/11908894-0.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a52e0258-9934-4b55-9ebf-2b855eca0fd3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46150,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,869,868,413],"class_list":["post-46149","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9688","tag-nasdaq-zlab","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total net product revenue of USD\u202f115.4\u202fmillion, a 13\u202f% year\u2011over\u2011year increase (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of Nuzyra (omadacycline) and Xacduro (Sulbactam\u2011Durlobactam), partially offset by a slowdown in Zejula (niraparib) sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46149\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows\" \/>\n<meta property=\"og:description\" content=\"Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total net product revenue of USD\u202f115.4\u202fmillion, a 13\u202f% year\u2011over\u2011year increase (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of Nuzyra (omadacycline) and Xacduro (Sulbactam\u2011Durlobactam), partially offset by a slowdown in Zejula (niraparib) sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46149\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-08T06:54:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-08T06:54:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows\",\"datePublished\":\"2025-11-08T06:54:58+00:00\",\"dateModified\":\"2025-11-08T06:54:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0806.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9688\",\"NASDAQ: ZLAB\",\"Zai Lab\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46149#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46149\",\"name\":\"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0806.webp\",\"datePublished\":\"2025-11-08T06:54:58+00:00\",\"dateModified\":\"2025-11-08T06:54:59+00:00\",\"description\":\"Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total net product revenue of USD\u202f115.4\u202fmillion, a 13\u202f% year\u2011over\u2011year increase (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of Nuzyra (omadacycline) and Xacduro (Sulbactam\u2011Durlobactam), partially offset by a slowdown in Zejula (niraparib) sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46149\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0806.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0806.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46149#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows - Insight, China&#039;s Pharmaceutical Industry","description":"Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total net product revenue of USD\u202f115.4\u202fmillion, a 13\u202f% year\u2011over\u2011year increase (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of Nuzyra (omadacycline) and Xacduro (Sulbactam\u2011Durlobactam), partially offset by a slowdown in Zejula (niraparib) sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46149","og_locale":"en_US","og_type":"article","og_title":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows","og_description":"Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total net product revenue of USD\u202f115.4\u202fmillion, a 13\u202f% year\u2011over\u2011year increase (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of Nuzyra (omadacycline) and Xacduro (Sulbactam\u2011Durlobactam), partially offset by a slowdown in Zejula (niraparib) sales.","og_url":"https:\/\/flcube.com\/?p=46149","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-08T06:54:58+00:00","article_modified_time":"2025-11-08T06:54:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46149#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46149"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows","datePublished":"2025-11-08T06:54:58+00:00","dateModified":"2025-11-08T06:54:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46149"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46149#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp","keywords":["Finanical Reports","HKG: 9688","NASDAQ: ZLAB","Zai Lab"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46149#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46149","url":"https:\/\/flcube.com\/?p=46149","name":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46149#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46149#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp","datePublished":"2025-11-08T06:54:58+00:00","dateModified":"2025-11-08T06:54:59+00:00","description":"Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third\u2011quarter 2025 financial results, reporting total net product revenue of USD\u202f115.4\u202fmillion, a 13\u202f% year\u2011over\u2011year increase (14\u202f% at constant exchange rate). Growth was driven by the launch\u2011phase uptake of Nuzyra (omadacycline) and Xacduro (Sulbactam\u2011Durlobactam), partially offset by a slowdown in Zejula (niraparib) sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46149#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46149"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46149#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp","width":1080,"height":608,"caption":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46149#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zai Lab Q3\u202f2025 Revenue Up 13% YoY to $115.4\u202fM, Led by Nuzyra and Xacduo; Zejula Slows"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0806.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46149"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46149\/revisions"}],"predecessor-version":[{"id":46152,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46149\/revisions\/46152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46150"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}